Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission

详细信息    查看全文

• 作者：Gretchen L. Snyder ; Kimberly E. Vanover ; Hongwen Zhu ; Diane B. Miller…
• 关键词：Schizophrenia ; Dopamine D2 receptor ; NMDA receptors ; Serotonin 5 ; HT2A receptor ; Social defeat ; Nucleus accumbens ; Microdialysis ; Mesocortical ; Nigrostriatal ; Serotonin transporter
• 刊名：Psychopharmacology
• 出版年：2015
• 出版时间：February 2015
• 年：2015
• 卷：232
• 期：3
• 页码：605-621
• 全文大小：939 KB
• 参考文献：1. Alimohamad H, Rajakumar N, Seah YH, Rushlow W (2005) Antipsychotics alter the protein expression levels of beta-catenin and GSK-3 in the rat medial prefrontal cortex and striatum. Biol Psychiatry 57:533-2 CrossRef
  2. Ancoli-Israel S, Vanover KE, Weiner DM, Davis RE, van Kammen DP (2011) Pimavanserin tartrate, a 5-HT(2A) receptor inverse agonist, increases slow wave sleep as measured by polysomnography in healthy adult volunteers. Sleep Med 12:134-41 CrossRef
  3. Auclair A, Drouin C, Cotecchia S, Glowinski J, Tassin J-P (2004) 5-HT_2A and α_1b-adrenergic receptors entirely mediate dopamine release, locomotor response, and behavioral sensitization to opiates and psychostimulants. Eur J Neurosci 20:3073-084 CrossRef
  4. Beaulieu J-M, Gainetdinov RR, Caron MG (2009) Akt/GSK3 signaling in the action of psychotropic drugs. Annu Rev Pharmacol Toxicol 49:327-47 CrossRef
  5. Berton O, McClung CA, Dileone RJ, Krishnan V, Renthal W, Russo SJ, Graham D, Tsankova NM, Bolanos CA, Rios M, Monteggeia DW, Nestler EJ (2006) Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science 311:864- CrossRef
  6. Bonhaus DW, Weinhardt KK, Taylor M, DeSouza A, McNeeley PM, Szczepanski K, Fontana DJ, Trinh J, Rocha CL, Dawson MW, Flippin LA, Eglen RM (1997) RS-102221: a novel high affinity and selective, 5-HT_2C receptor antagonist. Neuropharmacology 36:621- CrossRef
  7. Brennan JA, Graf R, Grauer SM, Navarra RL, Pulicicchio CM, Hughes ZA, Lin Q, Wantuch C, Rosenzweig-Lipson S, Pruthi F, Lai M, Smith D, Goutier W, van de Neut M, Robichaud AJ, Rotella D, Feenstra RW, Kruse C, Broqua P, Beyer CE, McCreary AC, Pausch MH, Marquis KL (2010) WS-50030 [7-[4-[3-(3-(1H-inden-3-yl)propyl]piperazin-1-yl)-1,3-benzoxazol-2(3H)-one]: a novel dopamine D₂ receptor partial agonist/serotonin uptake inhibitor with preclinical antipsychotic-like and antidepressant-like activity. J Pharmacol Exp Ther 332:190-10 CrossRef
  8. Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, Yocca R, Molinoff PB (2002) Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D₂ receptors. J Pharmacol Exp Ther 302:381- CrossRef
  9. Carty NC, Xu J, Kurup P, Brouillette J, Goebel-Goody SM, Austin DR, Yuan P, Chen G, Correa PR, Haroutunian V, Pittenger C, Lombroso PJ (2012) The tyrosine phosphatase STEP: implications in schizophrenia and the molecular mechanism underlying antipsychotic medications. Transl Psychiatr. doi:10.1038/tp.2012.63
  10. Chaudhury D, Walsh JJ, Friedman AK, Juarez B, Ku SM, Koo JW, Ferguson D, Tsai HC, Pomeranz L, Christoffel DJ, Nectow AR, Ekstrand M, Domingos A, Mazei-Robison MS, Mouzon E, Lobo MK, Neve RL, Friedman JM, Russo SJ, Deisseroth K, Nestler EJ, Han MH (2013) Rapid regulation of depression-related behaviours by control of midbrain dopamine neurons. Nature 493:532-36 CrossRef
  11. Clark D, Hjorth S, Carlsson A (1984) (+)- and (?-3-PPP exhibit different intrinsic activity at striatal dopamine autoreceptors controlling dopamine synthesis. Eur J Pharmacol 106:185- CrossRef
  12. Conn PJ, Sanders-Bush E (1984) Selective 5-HT-2 antagonists inhibit serotonin stimulated phosphatidylinositol metabolism in cerebral cortex. Neuropharmacology 23:993-96 CrossRef
  13. Creese I, Burt DR, Snyder SH (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic dru
• 刊物类别：Biomedical and Life Sciences
• 刊物主题：Biomedicine
  Pharmacology and Toxicology
  Psychiatry
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1432-2072

文摘

Rationale Schizophrenia remains among the most prevalent neuropsychiatric disorders, and current treatment options are accompanied by unwanted side effects. New treatments that better address core features of the disease with minimal side effects are needed. Objectives As a new therapeutic approach, 1-(4-fluoro-phenyl)-4-((6bR, 10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3-4-4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one (ITI-007) is currently in human clinical trials for the treatment of schizophrenia. Here, we characterize the preclinical functional activity of ITI-007. Results ITI-007 is a potent 5-HT2A receptor ligand (K i --.5?nM) with strong affinity for dopamine (DA) D2 receptors (K i --2?nM) and the serotonin transporter (SERT) (K i --2?nM) but negligible binding to receptors (e.g., H1 histaminergic, 5-HT2C, and muscarinic) associated with cognitive and metabolic side effects of antipsychotic drugs. In vivo it is a 5-HT2A antagonist, blocking (±)-2,5-dimethoxy-4-iodoamphetamine hydrochloride (DOI)-induced headtwitch in mice with an inhibitory dose 50 (ID50)--.09?mg/kg, per oral (p.o.), and has dual properties at D2 receptors, acting as a postsynaptic D2 receptor antagonist to block D-amphetamine hydrochloride (D-AMPH) hyperlocomotion (ID50--.95?mg/kg, p.o.), yet acting as a partial agonist at presynaptic striatal D2 receptors in assays measuring striatal DA neurotransmission. Further, in microdialysis studies, this compound significantly and preferentially enhances mesocortical DA release. At doses relevant for antipsychotic activity in rodents, ITI-007 has no demonstrable cataleptogenic activity. ITI-007 indirectly modulates glutamatergic neurotransmission by increasing phosphorylation of GluN2B-type N-methyl-d-aspartate (NMDA) receptors and preferentially increases phosphorylation of glycogen synthase kinase 3β (GSK-3β) in mesolimbic/mesocortical dopamine systems. Conclusion The combination of in vitro and in vivo activities of this compound support its development for the treatment of schizophrenia and other psychiatric and neurologic disorders.